Headlines about Henry Schein (NASDAQ:HSIC) have trended somewhat positive recently, Accern Sentiment reports. The research firm identifies negative and positive press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Henry Schein earned a coverage optimism score of 0.20 on Accern’s scale. Accern also assigned news stories about the company an impact score of 46.9058234012245 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

These are some of the media headlines that may have effected Accern’s scoring:

Henry Schein (NASDAQ:HSIC) traded up $1.20 during trading on Tuesday, reaching $76.04. 2,080,000 shares of the company’s stock traded hands, compared to its average volume of 1,620,000. The company has a current ratio of 1.55, a quick ratio of 0.86 and a debt-to-equity ratio of 0.30. Henry Schein has a 52-week low of $65.28 and a 52-week high of $93.50. The company has a market cap of $11,930.00, a price-to-earnings ratio of 21.91, a price-to-earnings-growth ratio of 1.91 and a beta of 0.99.

Henry Schein (NASDAQ:HSIC) last released its quarterly earnings results on Monday, November 6th. The company reported $0.87 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.90 by ($0.03). Henry Schein had a return on equity of 19.71% and a net margin of 4.52%. The firm had revenue of $3.16 billion for the quarter, compared to the consensus estimate of $3.05 billion. During the same quarter in the previous year, the business posted $0.84 EPS. The firm’s revenue for the quarter was up 10.3% compared to the same quarter last year. equities research analysts expect that Henry Schein will post 3.6 EPS for the current fiscal year.

Henry Schein declared that its board has initiated a stock repurchase program on Monday, September 18th that permits the company to buyback $400.00 million in shares. This buyback authorization permits the company to reacquire up to 6.3% of its stock through open market purchases. Stock buyback programs are generally an indication that the company’s board believes its shares are undervalued.

A number of brokerages recently issued reports on HSIC. Jefferies Group reiterated a “hold” rating and issued a $88.50 price objective on shares of Henry Schein in a report on Thursday, September 28th. Evercore ISI began coverage on shares of Henry Schein in a report on Thursday, January 4th. They issued an “outperform” rating and a $81.00 price objective for the company. Leerink Swann reiterated a “market perform” rating and issued a $77.00 price objective (down previously from $87.50) on shares of Henry Schein in a report on Tuesday, November 7th. Stephens began coverage on shares of Henry Schein in a report on Tuesday, November 28th. They issued an “equal weight” rating and a $76.00 price objective for the company. Finally, Royal Bank of Canada began coverage on shares of Henry Schein in a report on Tuesday, September 19th. They issued a “sector perform” rating and a $91.00 price objective for the company. Two investment analysts have rated the stock with a sell rating, seven have given a hold rating and eight have issued a buy rating to the company. Henry Schein has a consensus rating of “Hold” and a consensus price target of $84.23.

In other Henry Schein news, Director Barry J. Alperin sold 5,796 shares of the firm’s stock in a transaction that occurred on Friday, December 1st. The shares were sold at an average price of $70.76, for a total transaction of $410,124.96. Following the completion of the transaction, the director now owns 48,172 shares in the company, valued at approximately $3,408,650.72. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 1.19% of the stock is currently owned by company insiders.

COPYRIGHT VIOLATION WARNING: This article was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this article on another site, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The original version of this article can be viewed at https://www.thecerbatgem.com/2018/01/16/henry-schein-hsic-getting-somewhat-positive-media-coverage-report-shows.html.

About Henry Schein

Henry Schein, Inc is a provider of healthcare products and services primarily to office-based dental, animal health and medical practitioners. The Company operates through two segments: healthcare distribution, and technology and value-added services. The healthcare distribution segment distributes consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.

Insider Buying and Selling by Quarter for Henry Schein (NASDAQ:HSIC)

Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.